One of the main objectives of cancer immunotherapy is the activation and increase in number of antitumor effector cells. Recently, genetically modified tumor cell vaccines have been proposed for elicitation of antitumor effector cells. Native antigen ( Ag ) ( also known as MPT59 and antigen 85B ) of mycobacteria, which cross -reacts among mycobacteria species, may play an important biological role in host ± pathogen interaction because it elicits various helper T -cell type 1 immune responses. 
C
ancer cells form weakly immunogenic, tumor-associated antigens ( Ags ) that can be recognized by the host's immune surveillance systems. As with all nominal Ags, it is reasonable to speculate that an antitumor immune response involves recognition of tumor-associated Ags by the T helper (Th ) cells and cytotoxic T lymphocytes ( CTLs ) in the context of major histocompatibility complex ( MHC ) class II and class I molecules, respectively. 1 ± 3 However, the mechanisms of elimination of tumors are complicated because of the weak immunogenicity of tumor-associated Ags and the consequences of a variety of suppressive effects in tumor-bearing animals (reviewed in Refs. 4, 5 ). Therefore, various approaches to increasing a host's ability to elicit immune responses to tumors and investigation of factors causing immune suppression would have to be attempted in general.
Bacillus Calmette -Gue Ârin (BCG ) is an important clinical tool because of its profound immunostimulatory properties. It has been used worldwide to prevent tuberculosis, with a very low incidence of serious complications. 6, 7 Live BCG has also been successfully used clinically as an antitumor agent in the treatment of both superficial bladder cancer and malignant melanoma. 8 ± 11 BCG is able to stimulate the expression of interleukin ( IL) -1 to -4 and -6, tumor necrosis factor ( TNF ) -, and interferon (IFN )-from mononuclear cells. 12 ± 14 An important feature of the cellular immune response to mycobacterial infection involves the recruitment of a specific subset of Th cells. 15 ± 17 Th1 cells, a primary source of IFN -and IL -2, mediate CTL activity and delayed -type hypersensitivity (DTH ).
Native antigen ( Ag ), which produce biological roles of BCG in vivo and in vitro, is a cross -reacting substance that is widely distributed in Mycobacterium tuberculosis, Mycobacterium bovis, and nontuberculous mycobacteria, and it has been shown that this protein can induce strong Th1 -type immune responses in hosts sensitized with mycobacteria. 18 In the present study, we evaluated the effectiveness of cDNA of Ag derived from Mycobacterium kansasii as an immunostimulator for inducing antitumor immune responses in a bladder tumor model. We found that antitumor immune responses are readily induced in mice through immunization with tumor cells transfected with cDNA of Ag.
MATERIALS AND METHODS

Mice
In mice, unlike humans, studies using inbred and congenic strains have demonstrated the different fastness against BCG infection among each strain. 19 To give the resistance to BCG infection, C57BL /6 ( BCG -susceptible strain ) Â C3H / HeN ( BCG -resistant strain ) ( B6C3F1, H-2 b / k ) female mice and BALB / c (BCG -susceptible strain ) Â C3H /HeN (CC3HF1, H-2 d / k ) female mice were used in this study. These mice were housed in the Laboratory Animal Center of Mie University School of Medicine.
Priming to BCG
Mice were primed to BCG by intraperitoneally inoculating them with 0.01 mg (dry weight ) of BCG (Japan BCG Laboratory, Tokyo, Japan ) 4 weeks before injection or immunization of tumor cells.
Tumors and transfection
Mouse bladder tumor cells (MBT2 cells ) were transitional cell carcinoma originating in C3H /He mice by feeding them the chemical carcinogen N -[4 -5 -nitro -2 -fury -2 -thiazolyl ] formamide (FANFT ). 20 CMS5a is 3-methylcholanthrene ± induced fibrosarcoma of BALB /c origin. 21 The -Ag expression vector pcDNA has been constructed by cloning of a PCR product that possesses an Ag open reading frame lacking a signal sequence into KpnI±ApaI sites of pcDNA3.1 (Invitrogen CA ). 22 The human immunodeficiency virus env ( HIVenv ) expression vector pJWSUHIVenv was used as a control. MBT2 and CMS5a were transfected with pcDNA and a control vector using lipofectin (Gibco BRL, MD ) according to the manufacturer's instructions ( MBT2 / -k and CMS5a / -k ). All transfectants were selected in 1 mg /mL G418 (Gibco BRL ) and cloned by limiting dilution to obtain stable Ag -or HIVenv-expressing cells.
Peptide synthesis
The peptides used in this study included the mutated mitogen -activated kinase (ERK2) CMS5a CTL epitope ( QYIHSANVL; 9m ). 21 
Immunization with tumor cells
Transfected or nontransfected tumor cells were suspended in serum -free HBSS and treated with mitomycin C (MMC ). Mice were immunized by intradermal injection of tumor cells ( 1Â10 7 ) one to three times at 1-week intervals.
DTH responses
DTH responses to MBT2 cells were elicited by injecting 1Â10 4 MMC -treated MBT2 cells into the footpads of immunized mice. The degree of footpad swelling 24 hours after the injection was measured using a micrometer and expressed as mean increment SE of five mice /group.
Target cells
MBT2, EL -4 (control ) and P815 cells were used in this study. P815 cells were pulsed with peptide 9m and used as target cells.
Proliferative responses of spleen cells to MBT2 cells
The responding spleen cells obtained from immunized mice were treated with anti -CD4 (GK1.5 ), anti -CD8 ( Lyt2.2 ), or a medium and complement 23 to confirm the subset of effector cells, and then the cells were resuspended in complete medium and cultured at a concentration of 5Â10 5 cells per culture well together with 5Â10 4 MMC -treated MBT2 or MHC -matched control tumor cells ( EL -4 ) in a total volume of 0.2 mL. Each culture was performed in triplicate in 96 -well microculture plates and maintained in a humidified atmosphere of 5% CO 2 at 378C. The cultures were harvested using a cell harvester at 96 hours after a 6- 
Production of IFN -
Spleen cells from immunized mice (5Â10 6 ) were cultured with 1Â10
5 MMC -treated MBT2 cells in 24 -well culture plates at a volume of 2 mL. After incubation at 378C in a humidified incubator (5% CO 2 ) for 48 hours, culture supernatants were quantified by a standard enzyme -linked immunosorbent assay. Rat anti -( mouse IFN -) monoclonal antibodies were obtained from Beckton Dickinson. Recombinant mouse IFN -( PharMingen, CA ) was used to generate a standard curve.
Generation of CTL effector cells
Effector cells were derived from spleen cells as precursor CTLs. Aliquots of 5Â10 6 spleen cells were cocultured with or without 1Â10 5 MMC -treated MBT2 cells or autologous spleen cells labeled with peptide 9m at 378C in a CO 2 incubator. The effector cells generated were harvested after 5 days of culture.
Cytotoxic assay
Target cells were labeled with 51 Cr for 2 hours. The 51 Crlabeled target cells were incubated for 5 hours with effector cells. The target cells (P815 cells) were incubated at 378C in a 5% CO 2 atmosphere with 10 g /mL of the 9m or control peptide (hepatitis C virus E1 315 ±322 24 ) for 16 hours before labeling with 51 Cr. Spontaneous release varied from 5% to 10%. Percent lysis was calculated as [( experimental release À spontaneous release )/( 100% release À spontanentaneous release )]Â100. All experiments were performed more than three times, and each group consisted of five mice.
Blocking of cytolysis
Effector cells were preincubated with an anti -CD4 monoclonal antibody (mAb ) (GK1.5 ) or anti -CD8 mAb ( Lyt2.2 ) at a 1:50 dilution at 48C for 1 hour, and then the labeled target cells were added. Blocking of cytolytic activities by these mAbs was assessed by a 5-hour 51 Cr release assay.
Statistical analysis
Statistical analysis was performed using Mann -Whitney's U test and Kruskal -Wallis test. Values are expressed as the mean SD. A 95% confidence limit was taken as significant ( P <.05 ).
RESULTS
Tumor growth and survival of BCG -primed and unprimed mice injected with MBT2 or MBT2 / -k cells BCG -primed and unprimed mice were intradermally injected with 1Â10 5 of MBT2 or MBT2/ -k cells. Growth of tumor cells was observed in all mice, both BCG -primed and unprimed mice, that had been injected with MBT2 cells; however, growth of MBT2 / -k cells was not seen in 20% of the unprimed mice and in 60% of BCG -primed mice ( Fig  1a ) . There was no difference between the growth of MBT2/ -k cells and that of MBT2 cells in in vitro culture or in vivo experiments using scid mice, and control transfectant, cDNA of HIVenv, and empty plasmid -transfected cells were not rejected in mice that had been infected with recombinant vaccinia virus carrying the HIVenv gene or in noninfected mice (data not shown ). To know the recognition of Ag of tumor cells by the host, the mice that rejected MBT2/ -k cells were reinjected with wild -type MBT2 cells, and it was found that all of the mice rejected the MBT2 cells ( Fig 1b ) . Moreover, survival of BCG -primed mice that had been intravascularly injected with MBT2 / -k cells was prolonged, and 40% of these mice survived until the end of the observation period (Fig 1c ) . These results indicated that Ag of mycobacteria elicited antitumor immunity recognizing the tumor Ag, and that BCG sensitization enhanced this antitumor immune response induced by Ag of mycobacteria. ( Fig 3 ) . A significant component of this proliferative response was accounted for by CD4 + cells, because CD4 + cell ± depleted spleen cells exhibited a substantially reduced MBT2 -specific proliferative response. The observation that immunization of MBT2 / -k in BCG -primed mice elicited a CD4 + , proliferative T-lymphocyte response suggested that Ag induces a tumor-specific Th cell response.
Spleen cells from MBT2 / -k ± immunized mice produce IFN -with tumor specificity
We next measured the production of IFN -from spleen cells after stimulation in vitro with MMC -treated MBT2 cells. Spleen cells from BCG -primed mice immunized with MBT2/ -k cells produced a significant amount of IFNin the supernatant of the culture compared with spleen cells from the other three groups of mice after stimulation in vitro with MMC -treated wild -type MBT2 cells ( Fig 4 ) . Production of IFN -from spleen cells after stimulation in vitro with irrelevant tumor cells ( EL -4 ) was not observed ( data not shown). These results are in accordance with the results of proliferative responses against MBT2 cells in in vitro experiments, and they suggest that MBT2 -specific CD4 + T cells produce Th1 -type cytokines followed by proliferation.
Antitumor CD8 + CTLs are enhanced by Ag
Spleen cells from BCG -primed and unprimed mice immunized once with MBT2/ -k or MBT2 cells were stimulated in vitro with MBT2 cells or were not stimulated, and the lytic activities of the cells against MBT2 cells as CTL responses were assessed. Effector cells from BCG -primed mice immunized with MBT2 /-k cells showed greater MBT2-specific lytic activities than did effector cells from the other experimental mice ( P <.05 ) ( Fig 5) . MBT2 -specific effector cells from BCG -primed mice immunized with MBT2 / -k cells were cultured in a medium containing anti -CD4 or -CD8 mAb during 51 Cr release assay. The anti -CD8 mAb inhibited cytolysis against MBT2 cells, whereas the anti-CD4 mAb did not affect this effector cell function ( Fig 6 ) . Based on these findings, spleen cells from BCG -primed mice immunized with CMS5a or CMS5a/ -k were stimulated with peptide 9m, which has been reported to be the peptide epitope of CMS5a recognized by CD8 + CTL, 21 and the lytic activities of these cells against MHC -matched target cells pulsed with peptide 9m were assessed. Effector cells from CMS5a / -k ±immunized mice lysed peptide 9m -labeled target cells, whereas spleen cells from untransfected tumor, CMS5a, immunized mice did not show effector cell functions (P < .05) (Fig 7 ) . These results indicated that the immunization of tumor cells carrying Ag of mycobacteria elicited the activity of tumor-specific CD8 + CTLs.
DISCUSSION
Tumor vaccines are based on weakly immunogenic, tumorspecific Ags admixed with various immunostimulators for enhancement or restoration of immune responses against tumor cells. However, there are a number of different mechanisms by which tumor cells can avoid immune responses. The overall goal of immunogenetherapy for cancer is to correct one or more of these deficiencies and thereby facilitate immune recognition of tumor cells, resulting in the tumor developing immunity. In the present study, we showed a novel approach for inducing antitumor immune responses by utilizing a gene of Ag from mycobacteria.
Various genetically modified tumor vaccines have been reported to augment the recognition of tumor Ags and to enhance elicitation of effects of antitumor effector cells ( reviewed in Refs. 25 ± 27 ). There are two types of genetically modified tumor vaccine. One type uses cell surface molecules to enhance the recognition of Ags and the elicitation of activated antitumor effector cells. Induction of an antitumor effect by transfection with MHC and costimulatory molecules, B7 -1 or B7 -2, has been reported. 28 ± 37 These molecules have been thought to deliver the primary signal and maximal activation to effector cells by contact. The other type is one transfected with a cytokine gene. Various cytokines have been used as genetically modified tumor vaccines to elicit antitumor immune responses. 25,38 ± 46 These cytokines directly or indirectly elicit antitumor effects. Recently, the use of transfection with two or more combined genes has been considered for genetically modified tumor vaccines. These combined gene -transfection tumor vaccines have been shown to be more effective in eliciting antitumor effects, 47 ± 50 and it has been suggested that a combined modality gene transfection as tumor vaccines is important to contribute toward antitumor immune responses in the future. 51 Intravesical immunotherapy with BCG for superficial transitional cell carcinoma of the bladder is arguably the most effective form of antitumor immunotherapy to date, and one of the mechanisms of action is thought to be Th 1 -type immune responses induced by cytokine secretion. 52 ± 54 The protein of Ag is one of the major secretion products of mycobacterial species, and this protein has been suggested to be important for induction of host protection in which Th1 -type immune responses are involved 55, 56 Another important function of Ag is to bind fibronectin. 55, 57, 58 This function is thought to be crucial for binding phagocytic cells having fibronectin receptors, and this function might be a direct effect of BCG immunotherapy. 57, 59 We utilized these functions of Ag from mycobacteria to elicit antitumor immune responses as a genetically modified tumor vaccine.
The mechanisms of elicitation of antitumor immune responses by using an Ag ±transfecting tumor vaccine are thought to be as follows. Firstly, the incorporation of tumor cells into macrophages might be enhanced by the complex of Ag and fibronectin. This function might influence antigen -presenting cells (APCs ) having fibronectin receptors, VLA -4, including dendritic cells, and would therefore be important as a first step in immune responses. Secondly, cells activated by Ag may secrete several antitumor effector cell ± inducing or antitumor cytokines. In fact, the present study demonstrated the induction of a Th1 -type cytokine, IFN -, from spleen cells after stimulation with tumor cells in vitro and showed DTH responses to tumor cells in vivo in mice immunized with tumor cells carrying the gene of Ag ( Figures 2 and 4 ) . Thirdly, antitumor effector cells are readily enhanced by the addition of a Th epitope. We and others have reported that immunization with a conjugated peptide, Th epitope, and CTL epitope elicits higher CTL activity than does immunization with a CTL epitope alone in a peptide vaccine; 60, 61 moreover, this phenomenon was also found in a DNA vaccine strategy. 62 Immunization with plasmid DNA encoding a Th epitope and CTL epitope showed much higher CTL responses than did immunization with the same plasmid without a Th epitope. Transfection of Ag into tumor cells is thought to add a Th epitope to the tumor cells, and the same APCs may present both the CTL and Th epitopes through class I and class II MHC, respectively. 60, 61 In fact, recent studies have shown that induction of effective CTLs occurs in a cognate manner, such that both Th cells and CTLs recognize antigen on the same APCs through the CD40 ligand and CD40 molecule. 63 ± 65 For these reasons, a genetically modified vaccine using mycobacterial Ag suggests multiple effects to elicit antitumor immune responses.
The results of the present study suggest that a genetically modified tumor vaccine using Ag has several potential advantages over other genetically modified tumor vaccines due to the existence of multiple mechanisms for elicitation of antitumor immune responses. Moreover, the results showed the effectiveness of mycobacterial sensitization for enhancing antitumor immune responses in mice immunized with Ag ±transfected tumor cells. Because most humans have been sensitized by spontaneous infection or by vaccination with mycobacteria, this finding is valuable for the possible utilization of Ag as a tumor vaccine. The results of this study have provided evidence of the potential utility of Ag for the development of a genetically modified tumor vaccine. Japan, and the Ministry of Education, Culture, Sports, Science and Technology of Japan..
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